Oncotarget:TUG1或是一个有潜力的胆管癌预后相关因素和治疗靶点

2017-08-08 Emma MedSci原创

胆管癌(CCA)是指源于肝外胆管包括肝门区至胆总管下端的胆管的恶性肿瘤,其病因可能与胆管结石、原发性硬化性胆管炎等疾病有关。其对常规化学疗法或放射治疗的反应差,预后不良,胆管癌一直被认为属于放射线不敏感的肿瘤,对化学治疗也并不敏感,胆管癌较其他胃肠道肿瘤例如结肠癌化疗敏感性差。

胆管癌(CCA)是指源于肝外胆管包括肝门区至胆总管下端的胆管的恶性肿瘤,其病因可能与胆管结石、原发性硬化性胆管炎等疾病有关。其对常规化学疗法或放射治疗的反应差,预后不良,胆管癌一直被认为属于放射线不敏感的肿瘤,对化学治疗也并不敏感,胆管癌较其他胃肠道肿瘤例如结肠癌化疗敏感性差。长非编码RNA(lncRNA)在多种人类癌症中起关键作用,有研究报道lncRNA牛磺酸上调基因1(TUG1)与人类癌症发展相关。发表于Oncotarget一篇文章中,研究人员调查了TUG1对CCA的影响,探讨TUG1的表达模式,并评估其临床意义以及对于CCA的预后潜力。研究结果表明,TUG1或是一个有潜力的CCA预后相关因素和治疗靶点。研究人员调查了TUG1的一系列功能作用,包括细胞增殖、凋亡、迁移、侵袭和上皮-间质转化(EMT)。数据显示,CCA组织和细胞系中TUG1上调,TUG1的过表达与CCA患者的肿瘤大小(p=0.005),TNM期(p=0.013),术后复发(p=0.036)和总生存期(p=0.010)有关。RNA沉默后TUG1下调,减少了CCA细胞的生长并且增加了CCA细胞的凋亡。此外,TUG1抑制能

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1685780, encodeId=08f61685e8044, content=<a href='/topic/show?id=9c031e93356' target=_blank style='color:#2F92EE;'>#TUG1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17933, encryptionId=9c031e93356, topicName=TUG1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d85328261486, createdName=ms3117646317107274, createdTime=Thu Mar 08 05:16:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895335, encodeId=86761895335f5, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sat Feb 17 21:16:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795425, encodeId=fc931e954256d, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 29 23:16:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457472, encodeId=e22d145e472c6, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Thu Aug 10 07:16:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628291, encodeId=41a3162829165, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Thu Aug 10 07:16:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231578, encodeId=62282315e821, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Aug 08 19:20:38 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1685780, encodeId=08f61685e8044, content=<a href='/topic/show?id=9c031e93356' target=_blank style='color:#2F92EE;'>#TUG1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17933, encryptionId=9c031e93356, topicName=TUG1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d85328261486, createdName=ms3117646317107274, createdTime=Thu Mar 08 05:16:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895335, encodeId=86761895335f5, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sat Feb 17 21:16:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795425, encodeId=fc931e954256d, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 29 23:16:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457472, encodeId=e22d145e472c6, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Thu Aug 10 07:16:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628291, encodeId=41a3162829165, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Thu Aug 10 07:16:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231578, encodeId=62282315e821, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Aug 08 19:20:38 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1685780, encodeId=08f61685e8044, content=<a href='/topic/show?id=9c031e93356' target=_blank style='color:#2F92EE;'>#TUG1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17933, encryptionId=9c031e93356, topicName=TUG1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d85328261486, createdName=ms3117646317107274, createdTime=Thu Mar 08 05:16:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895335, encodeId=86761895335f5, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sat Feb 17 21:16:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795425, encodeId=fc931e954256d, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 29 23:16:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457472, encodeId=e22d145e472c6, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Thu Aug 10 07:16:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628291, encodeId=41a3162829165, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Thu Aug 10 07:16:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231578, encodeId=62282315e821, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Aug 08 19:20:38 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
    2017-08-29 仁医06
  4. [GetPortalCommentsPageByObjectIdResponse(id=1685780, encodeId=08f61685e8044, content=<a href='/topic/show?id=9c031e93356' target=_blank style='color:#2F92EE;'>#TUG1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17933, encryptionId=9c031e93356, topicName=TUG1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d85328261486, createdName=ms3117646317107274, createdTime=Thu Mar 08 05:16:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895335, encodeId=86761895335f5, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sat Feb 17 21:16:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795425, encodeId=fc931e954256d, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 29 23:16:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457472, encodeId=e22d145e472c6, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Thu Aug 10 07:16:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628291, encodeId=41a3162829165, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Thu Aug 10 07:16:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231578, encodeId=62282315e821, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Aug 08 19:20:38 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1685780, encodeId=08f61685e8044, content=<a href='/topic/show?id=9c031e93356' target=_blank style='color:#2F92EE;'>#TUG1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17933, encryptionId=9c031e93356, topicName=TUG1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d85328261486, createdName=ms3117646317107274, createdTime=Thu Mar 08 05:16:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895335, encodeId=86761895335f5, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sat Feb 17 21:16:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795425, encodeId=fc931e954256d, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 29 23:16:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457472, encodeId=e22d145e472c6, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Thu Aug 10 07:16:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628291, encodeId=41a3162829165, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Thu Aug 10 07:16:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231578, encodeId=62282315e821, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Aug 08 19:20:38 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1685780, encodeId=08f61685e8044, content=<a href='/topic/show?id=9c031e93356' target=_blank style='color:#2F92EE;'>#TUG1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17933, encryptionId=9c031e93356, topicName=TUG1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d85328261486, createdName=ms3117646317107274, createdTime=Thu Mar 08 05:16:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895335, encodeId=86761895335f5, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sat Feb 17 21:16:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795425, encodeId=fc931e954256d, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 29 23:16:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457472, encodeId=e22d145e472c6, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Thu Aug 10 07:16:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628291, encodeId=41a3162829165, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Thu Aug 10 07:16:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231578, encodeId=62282315e821, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Aug 08 19:20:38 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
    2017-08-08 虈亣靌

    学习了新知识

    0

相关资讯

盘点:近期胆管癌重大研究进展汇总

胆管癌是指源于肝外胆管包括肝门区至胆总管下端的胆管的恶性肿瘤。其病因可能与胆管结石、原发性硬化性胆管炎等疾病有关。临床可采用手术治疗、放射治疗、化学治疗等方法,但预后较差。【1】Hepatology:极早期肝内胆管癌或许不再是肝移植禁忌硬变肝存在肝内胆管癌(iCCA)是肝移植的禁忌证(LT)。最近的调查表明,“极早期”的iCCA(单个肿瘤≤2厘米)或许可以进行LT。因此研究者进行了这项国际多中

JNCI:每天饮用含糖饮料≥2杯,肝胆管癌风险高79%

日前,发表在《Journal of the National Cancer Institute》杂志上的研究表明,大量饮用含糖饮料如苏打水和果汁会增加胆囊癌的风险。该研究由瑞典卡罗林斯卡研究所的专家开展,为了探索苏打水和癌症风险之间的关系,他们分析了70000名成年人的饮食习惯调查数据,并对这些人进行了13年的随访调查,以了解他们的癌症诊断情况。这些参与者在1997年完成了饮食问卷调查,包括回答在

Am J Clin Nutr:来瞅瞅硒与肝癌有啥关系

The American Journal of Clinical Nutrition最近的一项研究结果显示,在癌症发病之前,一个更高的硒水平与欧洲人群中的肝细胞癌的风险降低相关。硒是一种矿物微量元素,存在于肉、蛋、谷物、洋葱等物质中,是控制氧化过程与癌症发展的关键。爱尔兰皇家外科学院的David J. Hughes博士进行了一项巢式病例对照研究,探究硒在癌症发病前,是否与各种肝胆肿瘤相关。研究者测

不同影像学检查方法在胆管癌诊治中的价值及局限性

胆管癌是发生于肝内或肝外胆管上皮的恶性肿瘤,最常见的组织病理学类型为腺癌,在肝恶性肿瘤中的发病率仅次于肝癌,近年来,胆管癌发病率和死亡率均呈快速增长趋势,其病因可能与肝内胆管结石、原发性硬化性胆管炎、寄生虫感染、胆管囊肿、毒物等有关。手术切除是胆管癌唯一的根治性治疗方法,因此胆管癌的早期检测至关重要。影像学检查可以明确胆管癌的生长位置、浸润程度,与邻近组织结构的关系,对于治疗前分期及治疗策略的

2016ESMO临床诊疗指南——胆管癌的诊断、治疗与随访发布

2016年9月,欧洲肿瘤内科学会(ESMO)发布了胆管癌的诊断、治疗与随访指南,指南主要内容包括:发病率和流行病学,诊断以及病理/生物分子,分期和风险评估,各种类型疾病的治疗,个体化医疗,监测和随访等。全文获取:下载地址:指南下载 (需要扣积分2分, 梅斯医学APP免积分下载) 

Cancer Cell:胆管癌是如何发生的?又该如何预防?

两种不同类型的癌症可以在肝脏发育。更常见的恶性肿瘤是由肝细胞产生的肝细胞癌。不常见的是肝脏胆管癌(胆管癌),其来源于胆管细胞或未分化肝细胞。两种癌症都难以治疗,近年来新诊断的病例数量有所增加。在美国,它们是今天癌症死亡的第二大原因,而且是新病例增长最快的癌症类型。